Member Info for avctIPmatters

Pay in shares will continue until additional cash is added to coffers from one of these options below :

"The Avacta management team and Board continue to explore all available pathways to provide optionality for financing its clinical therapeutics programs over the longer term, including divestment of the Diagnostics Division, partnering, attracting global specialist biotechnology investors and potentially a NASDAQ dual listing, on which further updates will be provided in the coming months."

gmcc

Website update

https://avacta.com/wp-content/uploads/2025/01/Avacta-Purchase-Ledger-Assistant-FINAL.pdf

URL Images Last Mod.

https://avacta.com/careers/ 0 2025-01-21 12:45 +00:00

https://avacta.com/careers/purchase-ledger-assistant/ 0 2025-01-21 12:45 +00:00

gmcc

Good Morning

https://www.onclive.com/

"Article

January 20, 2025

AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer

https://www.onclive.com/view/ava6000-elicits-clinically-meaningful-tumor-shrinkage-in-salivary-gland-cancer

OncLive.com

@OncLive

AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer

#Oncology #MedTwitter"

gmcc

Yes sreening started patients not yet dosed in phase1b , think most folks here understand that it was an external " quote " Tremedous results from phase1a so even better results will be expected in phase 1b , Very exciting data .

RNS states " Based on this favorable efficacy and safety data observed in the Phase 1a trial, Avacta has initiated three Phase 1b expansion cohorts in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer in the first and second line setting. Patients are screening and the first patients to be treated in these expansions are expected imminently in the US."

---------------------

Patients are screening and the first patients to be treated in these expansions are expected imminently in the US.

Christina Coughlin MD, PhD, CEO of Avacta, commented,

"These data highlight the transformative potential of our pre|CISION® peptide drug conjugates in expanding the efficacy of highly potent therapeutics and support our growing optimism in this program."

gmcc

Heading sounds better

"

NetEase Home > NetEase Account > TextApply for entry

中国新发现超大规模稀土矿

"90% of cancer patients had their disease under control, and the preliminary clinical results of peptide drug conjugates were positive"

Sorry last post bit confusing - if you click on Avacta it reveals RNS :

https://www.linkedin.com/pulse/jpm2025-executive-summary-day-four-its-wrap-gil-bashe-ffmxc

Refers

"Key Updates

Biopharma Highlights

Avacta: Lead candidate AVA6000 showed significant tumor shrinkage in Ph. 1b trials, with expansion cohorts underway for triple-negative breast cancer, soft tissue sarcoma, and salivary gland cancer"

Great to see Avacta mentioned : FINN Partners seem to be the original linkedin source quoting info from Avacta RNS - excellent find by alextak . So on the USA radar .

https://www.linkedin.com/company/finn-partners/posts/?feedView=all

https://www.finnpartners.com/sector/health/global-health-impact/

--------------------

FINN PartnersFINN Partners

59,071 followers59,071 followers

16h • 16 hours ago

Follow

And that’s a wrap on hashtag#JPM25! What a week in San Francisco. With promising trials, deals closed, and partnerships sealed, 2025 holds much potential for continued momentum in all sectors. We hope you have found our recaps helpful - our IR and marcomm teams stand ready to help you deliver on your 2025 goals! Please reach out.

https://www.linkedin.com/feed/update/urn:li:activity:7286087161991376896/

---------------------------

Might be of interest FINN Partners video on why attend the conference .

https://www.youtube.com/watch?v=r7-Z-5HDo0U

"18 Dec 2024 #health #innovation #communication

Top experts from FINN Partners’ Global Health Practice sat down for an exclusive webinar exploring what makes the J.P. Morgan Healthcare Conference a must-attend event for stakeholders across the entire #health sector and how to navigate the world’s most important positioning and investment gathering."

gmcc

Member of Avacta Scientific Advisory Board -MSK AVA6000 clinical trial Co-Investigators

https://www.mskcc.org/cancer-care/clinical-trials/22-428

Might be spreading the word : Head & Neck cancers

"January 16th to 18th 2025 | Dubai World Trade Centre"

https://ifhnos.net/

https://x.com/MSKCancerCenter/status/1880019200976253113/photo/1

--------------------

Memorial Sloan Kettering Cancer Center

@MSKCancerCenter

MSK Head and Neck Cancer experts Dr. Jatin Shah, Dr.

@imrtlee

, and Dr.

@AlanHoMDPhD

, will be speaking at multiple sessions at the International Federation of Head and Neck Oncologic Societies (IFHNOS) 2025 Head and Neck Cancer Summit in Dubai.

Discussion topics include the future of head and neck cancer and the latest techniques and best practices in using surgery, radiotherapy, and immunotherapy to treat head and neck cancers."

gmcc

Courtesy of X - many thanks for sharing :

https://x.com/Blueberrymgmnt/status/1880213751905022334

"

Marty McFly

@Blueberrymgmnt

·

2h

Metastases promote drug resistance through genetic diversity, protective microenvironments, and stromal interactions that provide survival signals, making cancer cells more adaptable and less sensitive to treatment.

Marty McFly

@Blueberrymgmnt

·

2h

Metastases require targeted drug delivery due to genetic diversity, protective microenvironments, and stromal interactions that promote drug resistance.

Standard drugs struggle to penetrate and remain effective, making precise targeting essential for treatment.

Marty McFly

@Blueberrymgmnt

·

2h

Standard dox isn’t effective against metastases. A targeted version is used, ie liposomal or doxil.

The targeted dose needs to be higher than what can be delivered systemically, I.e. bang for buck can’t be delivered using naked dox.

Naked dox is not effective enough.

Marty McFly

@Blueberrymgmnt

·

2h

90% of patients in the metastatic setting, die. Its presence has a huge impact on outcomes. To overcome requires;

💉High specificity

💉High intratumoral dose

AVA6000 destroys metastases. Therefore, delivers high amounts of dox to the tumour, specifically.

Marty McFly

@Blueberrymgmnt

·

2h

The fact metastases contain more CAFs than the primary legion, highlights the effectiveness of AVA6000s MoA.

🚨We’re celebrating the platform technology here; not the drug. 🚨"

Would be great if Avacta can join the NASDAQ biotech club : Avacta have a unique delivery platform solution :

"About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients."

Avacta biotech IP assets will attract better value on NASDAQ

Examples of others joining NASADQ .

------------------------

"Top 5 Small-cap Biotech Stocks (Updated January 2025)!

"According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.5 percent from now to 2034, reaching a valuation of US$4.61 trillion."

https://www.nasdaq.com/articles/top-5-small-cap-biotech-stocks-updated-january-2025

Should be a very exciting year - This Tortoise happy to wait for one huge shareholder payload ,

gmcc

Good coverage for Avacta :

"There is an unmet need in salivary gland cancer, with Avacta noting the lack of a standard of care for people with distant metastasis and a five-year survival rate of 43%, but the condition is relatively rare. Success in triple negative breast cancer would move Avacta into a larger indication. "

https://www.fiercebiotech.com/biotech/avacta-expands-peptide-drug-conjugate-study-after-seeing-10-response-rate

gmcc

Getting on with day job :

Global market Arab Health Medical Expo

📅 January 27-30, 2025

https://www.linkedin.com/company/coris-bioconcept/posts/?feedView=all

"CORIS BIOCONCEPTCORIS BIOCONCEPT

2,807 followers2,807 followers

22h • Edited • 22 hours ago

Follow

🔜 Arab Health Medical Expo

📅 January 27-30, 2025

📍 DUBAI World Trade Centre

🤝 Booth Z2.A58 - Belgian Pavilion

Our COO, Sebastien Goenen, will attend Arab Health congress in DUBAI ✈️

Don't miss the opportunity to come and discuss AntiMicrobial Resistance and discover our RESIST product range to tackle this global emerging threat.

www.corisbio.com

info@corisbio.com

hashtag#ArabHealth hashtag#DUBAI hashtag#AMR hashtag#RapidTests hashtag#FightResistance"

gmcc

Matthew Vincent : Close previous connection with Tufts /Avacta/PB is listed on patents .

https://patents.justia.com/inventor/matthew-p-vincent

Very old news current situation

http://affyxell.com/company/people.php

Fyi : Think Brian might be busy :good luck .

"

Christina Coughlin

@coughlin582

·

12m

We are thrilled to welcome Brian to the Leadership team at Avacta. His knowledge and experience will combine to do great things for the Company

Welcome to Avacta Brian!"

#PeptidesCreateHope

#LetsDoThis

#HopeWithoutCompromise

Thanks for sharing : CEO "Look out for news on significant expansion plans with existing partners & more deals in the pipeline. Targeting further growth!"

gmcc

Avacta have a better solution :

https://x.com/Blueberrymgmnt/status/1878768151284027729

Informative info courtesy X

Innovating Oncology Treatment: The Role of ADCs and Strategic Partnerships in Shaping the Future of Cancer Care – An MIT Sloan Career Development Office Conversation with Ken Keller, Chairman of the Board, President, and CEO of Daiichi Sankyo, Inc.

https://cdo.mit.edu/blog/2025/01/08/innovating-oncology-treatment-the-role-of-adcs-and-strategic-partnerships-in-shaping-the-future-of-cancer-care-an-mit-sloan-career-development-office-conversation-with-ken-keller-chairman/

"In terms of innovative funding models, this need for speed and risk-sharing has driven early-stage companies, particularly those without the extensive resources of a Merck or AstraZeneca, to consider earlier alliances with larger companies. Mergers and acquisitions (M&A), as well as drug partnerships, are becoming more prominent as companies seek to leverage larger firms’ capabilities to stay competitive in this accelerated environment. Essentially, we’re witnessing a shift where partnerships and collaborations are not only a strategic choice but, in many cases, a requirement for sustained innovation and financial viability."

Nice spot LLP

"THRUST Strategic Communications

https://thruststrategiccommunications.com/

"LIFE SCIENCE STRATEGIC ADVISORY

DONE DIFFERENTLY

We are a team of specialized experts in biopharma finance, investor relations, and corporate communications.

Every THRUST advisor has been in-house at public companies and knows the in’s and out’s of strategic planning and building and implementing a comprehensive IR/PR program. With a unique focus on financing strategy and execution, and a demonstrated track record, we are more than your standard "IR shop."

We know what good looks like and how to get it done."

gmcc

Courtesy of :

https://x.com/Blueberrymgmnt/status/1877292845083578583/photo/1

Marty McFly

@Blueberrymgmnt

·

7m

#AVCT

$50m upfront

$1.15bn out turn

Preclinical candidate licensed by Avenzo to Duality based on *potential*.

“Based on preclinical studies, we believe AVZO-1418/DB-1418 has the potential to offer enhanced therapeutic benefits over other therapies.”

Alistair paid the price for bad execution - Securing the IP rights was his master stroke - affimers & Avacta pre|CISION® platform a proprietary warhead delivery system will eventually provide handsome investment returns. So wish him well & good luck .

Blame game is for losers - Believing in the science is for winners well worth the wait .

gmcc .